Abbott Laboratories reported a slight beat on first-quarter earnings and revenue, with sales up 7.8% and adjusted EPS rising 6%. However, shares fell 3.2% as the company warned that its recent $23 billion acquisition of Exact Sciences will reduce its 2026 earnings outlook by about $0.20 per share. Abbott expects full-year 2026 sales growth of 6.5% to 7.5% and remains confident in long-term growth despite near-term dilution from the acquisition. CEO Robert Ford highlighted the acquisition's strategic value in expanding Abbott's oncology diagnostics business in a high-growth market.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
